Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ATF1 | P18846 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531715 | 0.84 | TRPA1 (0.52) | NOTUMTRPA1CYP1A2LMNAALDH1A1 | |
| SCHEMBL23668746 | 0.84 | KDM4E (0.59) | KDM4ELMNANFKB1HSD17B10ALDH1A1 | |
| SCHEMBL19002523 | 0.83 | NOTUM (0.64) | NOTUMKDM4ELMNANFKB1HSD17B10 | |
| SCHEMBL1999038 | 0.82 | NOTUM (0.77) | NOTUMKDM4ELMNANFKB1ALDH1A1 | |
| SCHEMBL475762 | 0.82 | NOTUM (0.77) | NOTUMKDM4ELMNANFKB1HSD17B10 | |
| SCHEMBL19002525 | 0.79 | NOTUM (0.59) | NOTUMTRPA1KDM4ELMNAHSD17B10 | |
| SCHEMBL5119432 | 0.79 | NOTUM (0.59) | NOTUMCYP1A2KDM4ELMNAATF1 | |
| SCHEMBL4966922 | 0.78 | TRPA1 (0.53) | TRPA1CYP1A2LMNAALDH1A1MAPT | |
| SCHEMBL346670 | 0.78 | NOTUM (1.00) | NOTUMKDM4ELMNANFKB1ALDH1A1 | |
| SCHEMBL21839899 | 0.78 | NOTUM (0.53) | NOTUMKDM4ELMNANFKB1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | NOTUM 3726/4885TRPA1 3849/4885CYP1A2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.